Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy-An Overview

Biomedicines. 2022 Nov 15;10(11):2932. doi: 10.3390/biomedicines10112932.

Abstract

Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four-stranded DNA helical structure constituted of guanine-rich nucleic acids, and its stabilization impairs telomere replication, triggering the activation of several protein factors at telomere levels, including Topos. Thus, the pharmacological intervention through the simultaneous G4 stabilization and Topos inhibition offers a new opportunity to achieve greater antiproliferative activity and circumvent cellular insensitivity and resistance. In this line, dual ligands targeting both Topos and G4 emerge as innovative, efficient agents in cancer therapy. Although the research in this field is still limited, to date, some chemotypes have been identified, showing this dual activity and an interesting pharmacological profile. This paper reviews the available literature on dual Topo inhibitors/G4 stabilizing agents, with particular attention to the structure-activity relationship studies correlating the dual activity with the cytotoxic activity.

Keywords: G-quadruplexes; cancer; dual ligand; small molecules; telomeres; topoisomerases.

Publication types

  • Review

Grants and funding

The author would like to thank the University of Pisa (Fondi di Ateneo 2020).